IOM Makes Recommendations on Postmarketing Drug Oversight

Published Online: Thursday, June 14, 2012
Follow Pharmacy_Times:

The FDA should have a plan for postmarketing safety monitoring of each drug that it approves, according to a report recently released by an Institute of Medicine (IOM) committee. The report also offers general guidelines for when the agency should require a postmarketing safety study.

Each drug’s Benefit and Risk Assessment Management Plan (BRAMP) would be publicly available and would include a description and risk-benefit assessment of any safety questions that exist when the drug is approved, as well as any that emerge once it is marketed, along with details on any regulatory actions taken and their results. Much of this information is already gathered by the FDA, the committee noted, although it is not centralized and easily accessible.

In general, the committee recommended that postmarketing safety studies be required when regulatory decisions can’t be made with existing safety evidence, when research can be designed to help inform a regulatory decision that can be made in a timely fashion, and when the rights and interests of research participants can be adequately protected. The committee notes that randomized controlled studies may be difficult to conduct once a drug has been approved, so observational studies may be preferred for postmarketing safety evaluation on ethical and practical grounds.

Related Articles
Pharmacists can play an important role in OTC acetaminophen safety.
To help visitors to more easily find disposal locations in their area, AWARXE has launched a location-based search tool.
Although the proposed USP General Chapter <800> is not anticipated to take effect for at least the next 2 years, an expert panel described how pharmacists can start preparing for the new standards in handling hazardous drugs.
Law enforcement and emergency response officials in Norfolk County, MA, have kicked off a Prescription Drug Safety Initiative to help pharmacies identify possible signs of fraud or abuse.
Latest Issues